Clinical Trial Update: Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) [Phase 4]

View source ↗

Summary

This Phase 4 extension study evaluates the efficacy and safety of deferasirox in transfusion-dependent beta-thalassemia patients with iron overload, extending t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta Thalassemia Major
• Hemosiderosis
• Iron Overload

Drugs mentioned

• Exjade (deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Beta-thalassemia Major, Hemosiderosis | Phase 4 | Status: COMPLETED | Results posted: 2011-07-29